Donepezil – Treatment of Agitation in Alzheimer’s Disease

Agitation is a common and distressing symptom in patients with Alzheimer’s disease. Cholinesterase inhibitors improve cognitive outcomes in such patients, but the benefits of these drugs for behavioral disturbances are unclear.

Randomly assigned 272 patients with Alzheimer’s disease who had clinically significant agitation and no response to a brief psychosocial treatment program to receive 10 mg of donepezil per day (128 patients) or placebo (131 patients) for 12 weeks.

In this 12-week trial, donepezil was not more effective than placebo in treating agitation in patients with Alzheimer’s disease.